ストックスクリーナーアプリを入手
26.97
14.33%
3.38
アフターアワーズ：
26.95
-0.02
-0.07%
前日終値:
$23.59
開ける：
$24.12
24時間の取引高:
67,529
Relative Volume:
1.13
時価総額：
$264.71M
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-3.44%
1か月 パフォーマンス:
+39.24%
6か月 パフォーマンス:
+0.00%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$24.00
$27.32
1週間の範囲:
$23.42
$28.78
52週間の値動き範囲:
$11.17
$29.27
Palvella Therapeutics Inc Stock (PVLA) Company Profile
PVLA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PVLA
Palvella Therapeutics Inc
|
26.97 | 264.71M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.49 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
625.60 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
583.62 | 35.60B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
266.83 | 34.53B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
274.78 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Palvella Therapeutics Inc Stock (PVLA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-26 | 開始されました | Stifel | Buy |
| 2025-03-07 | 開始されました | Scotiabank | Sector Outperform |
| 2025-02-20 | 開始されました | Canaccord Genuity | Buy |
| 2025-02-05 | 開始されました | TD Cowen | Buy |
| 2024-12-26 | 開始されました | H.C. Wainwright | Buy |
| 2024-12-18 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-03-13 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2019-07-30 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2019-05-14 | 開始されました | Robert W. Baird | Outperform |
| 2018-03-19 | 開始されました | Evercore ISI | Outperform |
| 2018-03-19 | 開始されました | Jefferies | Buy |
| 2018-01-16 | 繰り返されました | H.C. Wainwright | Buy |
| 2017-05-30 | 開始されました | Rodman & Renshaw | Buy |
| 2016-08-05 | 再開されました | ROTH Capital | Buy |
| 2015-08-12 | 開始されました | JMP Securities | Mkt Outperform |
| 2015-07-27 | 開始されました | Oppenheimer | Outperform |
| 2015-07-22 | 開始されました | ROTH Capital | Buy |
すべてを表示
Palvella Therapeutics Inc (PVLA) 最新ニュース
Palvella Therapeutics Announces Late-Breaking Presentation at Global Pediatric Dermatology Congress - MyChesCo
Palvella Therapeutics Announces Late-Breaking Oral Presentation at the 15th World Congress of Pediatric Dermatology - The Manila Times
Groundbreaking Phase 3 Results: First-Ever Treatment for Rare Lymphatic Disease Heads to Major Congress - Stock Titan
Palvella Therapeutics Reports 2024 Financial Results and Advances Rare Disease Pipeline - MyChesCo
Is Palvella Therapeutics Inc. (PVLA) the Best Performing NASDAQ Stock So Far in 2025? - Insider Monkey
Stifel maintains $45 target on Palvella Therapeutics stock By Investing.com - Investing.com Australia
Stifel maintains $45 target on Palvella Therapeutics stock - Investing.com
Earnings call transcript: Palvella Therapeutics Q4 2024 reveals strategic focus By Investing.com - Investing.com South Africa
Earnings call transcript: Palvella Therapeutics Q4 2024 reveals strategic focus - Investing.com
Palvella Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Palvella Therapeutics Reports 2024 Financial Results and Updates - TipRanks
PALVELLA THERAPEUTICS, INC. SEC 10-K Report - TradingView
Palvella Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewswire
Palvella Therapeutics to Announce 2024 Financial Results and Host Investor Call on March 31, 2025 - MSN
Palvella Therapeutics (PVLA) to Release Earnings on Monday - Defense World
Palvella Therapeutics Inc expected to post a loss of 67 cents a shareEarnings Preview - TradingView
Brokerages Set Palvella Therapeutics (NASDAQ:PVLA) Price Target at $43.20 - Defense World
Palvella Therapeutics (PVLA) Projected to Post Earnings on Monday - MarketBeat
Palvella Therapeutics (NASDAQ:PVLA) Now Covered by Stifel Nicolaus - Defense World
Is Palvella Therapeutics (PVLA) the Best Performing Stock So Far in 2025? - Yahoo
Stifel Initiates Coverage of Palvella Therapeutics (PVLA) with Buy Recommendation - Nasdaq
Stifel Initiates Palvella Therapeutics at Buy With $45 Price Target - Marketscreener.com
Stifel analysts initiate Palvella Therapeutics stock with Buy, $45 target By Investing.com - Investing.com Canada
Jones Trading Initiates Coverage of Palvella Therapeutics (PVLA) with Buy Recommendation - Nasdaq
Stifel initiates Palvella Therapeutics with a buy, $45 target By Investing.com - Investing.com Canada
Stifel analysts initiate Palvella Therapeutics stock with Buy, $45 target - Investing.com
Stifel initiates Palvella Therapeutics with a buy, $45 target - Investing.com
Palvella Therapeutics initiated with a Buy at Stifel - TipRanks
Palvella Therapeutics (PVLA) Projected to Post Earnings on Thursday - Defense World
Palvella Therapeutics to Host Full Year 2024 Financial Results Conference Call on March 31, 2025 - GlobeNewswire
Palvella Therapeutics, Inc. Scheduled to Report Full Year 2024 Financial Results on March 31, 2025 - Nasdaq
Rare Disease Leader Palvella Therapeutics Unveils 2024 Financial Performance March 31 - StockTitan
Lucid Capital sets $49 target on Palvella Therapeutics stock By Investing.com - Investing.com UK
Individual investors who hold 41% of Palvella Therapeutics, Inc. (NASDAQ:PVLA) gained 12%, insiders profited as well - Yahoo Finance
Palvella Therapeutics Insider Confidence Rewarded, Stock Hits US$308m Market Cap - simplywall.st
Pieris Pharmaceuticals stock soars to 52-week high of $29.01 - Investing.com
PavellaUndiscovered Biotechnology Stock - TradingView
PalvellaUndiscovered Biotechnology Stock - Barchart
Palvella Therapeutics (NASDAQ:PVLA) Coverage Initiated at Scotiabank - Defense World
Scotiabank Initiates Coverage of Palvella Therapeutics (PVLA) with Sector Outperform Recommendation - Nasdaq
Scotiabank sets Palvella stock to Sector Outperform, $50 target - Investing.com
Scotiabank sets Palvella stock to Sector Outperform, $50 target By Investing.com - Investing.com UK
Palvella Therapeutics initiated with an Outperform at Scotiabank - TipRanks
Pieris Pharmaceuticals stock hits 52-week high at $22.56 By Investing.com - Investing.com Canada
Pieris Pharmaceuticals stock hits 52-week high at $22.56 - Investing.com
Palvella Therapeutics Enhances Investor Relations with New Presentation - TipRanks
Why Palvella Therapeutics, Inc. (PVLA) is Skyrocketing So Far in 2025 - MSN
Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025 - Insider Monkey
Palvella Therapeutics to Present at TD Cowen 45th Annual Healthcare Conference - MSN
Palvella Therapeutics Inc (PVLA) 財務データ
Palvella Therapeutics Inc (PVLA) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
2.00%
大文字化:
|
ボリューム (24 時間):